TICKERNOMICS Sign up
Last Update: 2023-12-23 06:02:32
Citius Pharmaceuticals Inc. ( CTXR ) https://www.citiuspharma.com
0.76USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-9.69%
CTXR
SPY
30.72%
-31.36%
CTXR
SPY
112.82%
-29.44%
CTXR
SPY
201.04%
CTXR
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
116.10
83.40
0.52
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-3.80
0.00
1.18
-163.22
0.00
-2.38
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.5382
-31.21
-30.93
1.13
Other Earnings and Cash Flow Stats:
Citius Pharmaceuticals Inc. ( CTXR ) Net Income TTM ($MM) is -28.87
Citius Pharmaceuticals Inc. ( CTXR ) Operating Income TTM ($MM) is -32.39
Citius Pharmaceuticals Inc. ( CTXR ) Owners' Earnings Annual ($MM) is 0.00
Citius Pharmaceuticals Inc. ( CTXR ) Current Price to Owners' Earnings ratio is 0.00
Citius Pharmaceuticals Inc. ( CTXR ) EBITDA TTM ($MM) is -32.01
Citius Pharmaceuticals Inc. ( CTXR ) EBITDA Margin is 0.00%
Capital Allocation:
Citius Pharmaceuticals Inc. ( CTXR ) has paid 0.00 dividends per share and bought back -7.692981 million shares in the past 12 months
Citius Pharmaceuticals Inc. ( CTXR ) has reduced its debt by 0.095932 million USD in the last 12 months
Capital Structure:
Citius Pharmaceuticals Inc. ( CTXR ) Interest-bearing Debt ($MM) as of last quarter is 0
Citius Pharmaceuticals Inc. ( CTXR ) Annual Working Capital Investments ($MM) are 31
Citius Pharmaceuticals Inc. ( CTXR ) Book Value ($MM) as of last quarter is 98
Citius Pharmaceuticals Inc. ( CTXR ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Citius Pharmaceuticals Inc. ( CTXR ) has 33 million in cash on hand as of last quarter
Citius Pharmaceuticals Inc. ( CTXR ) has 5 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Citius Pharmaceuticals Inc. ( CTXR ) has 153 common shares outstanding as of last quarter
Citius Pharmaceuticals Inc. ( CTXR ) has 0 million USD of preferred stock value
Academic Scores:
Citius Pharmaceuticals Inc. ( CTXR ) Altman Z-Score is 3.15 as of last quarter
Citius Pharmaceuticals Inc. ( CTXR ) Piotroski Score is 0.00 as of last quarter
Corporate Governance:
Citius Pharmaceuticals Inc. ( CTXR ) largest shareholder is GSA Capital Partners LLP owning 198492 shares at 0.15 ($MM) value
HOLUBIAK MYRON Z(President and CEO) Bought 15000 shares of Citius Pharmaceuticals Inc. ( CTXR ) for the amount of $0.00 on 2021-10-11
7.75% of Citius Pharmaceuticals Inc. ( CTXR ) is held by insiders, and 15.68% is held by institutions
Citius Pharmaceuticals Inc. ( CTXR ) went public on 2017-07-06
Other Citius Pharmaceuticals Inc. ( CTXR ) financial metrics:
FCF:-148.45
Unlevered Free Cash Flow:0.00
EPS:-0.22
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-34.72
Beta:1.13
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Citius Pharmaceuticals Inc. ( CTXR ) :
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, preion products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.